Advertisement

Cognitive Dysfunction in the Workplace: Focus on Depression

  • Raymond W. LamEmail author
  • Carol Persad
Chapter
Part of the Integrating Psychiatry and Primary Care book series (IPPC)

Abstract

Major depressive disorder (MDD) is a common and burdensome mental health condition that is associated with significant occupational disability. Cognitive dysfunction, especially in neurocognitive domains of attention, memory, and executive functioning, is a well-recognized core feature of MDD that contributes to impairment in work functioning. Although there are many evidence-based treatments for MDD, neurocognitive deficits can persist even when other depressive symptoms are in remission after treatment. Despite the importance of cognition in mediating functional and occupational recovery, there has been little study of treatments that specifically address depression-associated cognitive dysfunction. In this chapter, we review the importance of cognitive dysfunction as it relates to workplace impairment in MDD, summarize the specific cognitive effects of evidence-based psychological and pharmacological treatments, and provide some principles to guide optimal treatment for working patients with MDD.

Keywords

Depression Psychosocial functioning Occupation Work Cognition Neuropsychology Psychotherapy Pharmacotherapy Antidepressants Cognitive remediation Presenteeism Productivity Functional recovery 

References

  1. 1.
    Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145:39–48.CrossRefGoogle Scholar
  2. 2.
    Knight MJ, Baune BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31:26–31.CrossRefGoogle Scholar
  3. 3.
    Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029–40.CrossRefGoogle Scholar
  4. 4.
    Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry. 2008;69:1122–30.CrossRefGoogle Scholar
  5. 5.
    Douglas KM, Gallagher P, Robinson LJ, Carter JD, McIntosh VV, Frampton CM, Watson S, Young AH, Ferrier IN, Porter RJ. Prevalence of cognitive impairment in major depression and bipolar disorder. Bipolar Disord. 2018;20:260–74.CrossRefGoogle Scholar
  6. 6.
    Beblo T, Sinnamon G, Baune BT. Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors. Neuropsychol Rev. 2011;21:337–59.CrossRefGoogle Scholar
  7. 7.
    Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016;16:455–63.CrossRefGoogle Scholar
  8. 8.
    Evans VC, Chan SS, Iverson GL, Bond DJ, Yatham LN, Lam RW. Systematic review of neurocognition and occupational functioning in major depressive disorder. Neuropsychiatry. 2013;3:97–105.CrossRefGoogle Scholar
  9. 9.
    Bearden CE, Glahn DC, Monkul ES, Barrett J, Najt P, Villarreal V, Soares JC. Patterns of memory impairment in bipolar disorder and unipolar major depression. Psychiatry Res. 2006;142:139–50.CrossRefGoogle Scholar
  10. 10.
    Cotrena C, Branco LD, Shansis FM, Fonseca RP. Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life. J Affect Disord. 2016;190:744–53.CrossRefGoogle Scholar
  11. 11.
    Zaninotto L, Solmi M, Veronese N, Guglielmo R, Ioime L, Camardese G, Serretti A. A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression. J Affect Disord. 2016;201:15–24.CrossRefGoogle Scholar
  12. 12.
    MacQueen GM, Memedovich KA. Cognitive dysfunction in major depression and bipolar disorder: assessment and treatment options. Psychiatry Clin Neurosci. 2017;71:18–27.CrossRefGoogle Scholar
  13. 13.
    Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176:183–9.CrossRefGoogle Scholar
  14. 14.
    Biringer E, Mykletun A, Sundet K, Kroken R, Stordal KI, Lund A. A longitudinal analysis of neurocognitive function in unipolar depression. J Clin Exp Neuropsychol. 2007;29:879–91.CrossRefGoogle Scholar
  15. 15.
    Bora E, Harrison BJ, Yücel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43:2017–26.CrossRefGoogle Scholar
  16. 16.
    Knight MJ, Air T, Baune BT. The role of cognitive impairment in psychosocial functioning in remitted depression. J Affect Disord. 2018;235:129–34.CrossRefGoogle Scholar
  17. 17.
    Bubonya M, Cobb-Clark D, Wooden M. Mental health and productivity at work: does what you do matter? Labour Econ. 2017;46:150–65.CrossRefGoogle Scholar
  18. 18.
    Laing SS, Jones SM. Anxiety and depression mediate the relationship between perceived workplace health support and presenteeism: a cross-sectional analysis. J Occup Environ Med. 2016;58:1144–9.CrossRefGoogle Scholar
  19. 19.
    Lee SA, Ju YJ, Han KT, Choi JW, Yoon HJ, Park EC. The association between loss of work ability and depression: a focus on employment status. Int Arch Occup Environ Health. 2017;90:109–16.CrossRefGoogle Scholar
  20. 20.
    Lerner D, Henke RM. What does research tell us about depression, job performance, and work productivity? J Occup Environ Med. 2008;50:401–10.CrossRefGoogle Scholar
  21. 21.
    Kalechstein AD, Newton TF, van Gorp WG. Neurocognitive functioning is associated with employment status: a quantitative review. J Clin Exp Neuropsychol. 2003;25:1186–91.CrossRefGoogle Scholar
  22. 22.
    Adler DA, McLaughlin TJ, Rogers WH, Chang H, Lapitsky L, Lerner D. Job performance deficits due to depression. Am J Psychiatry. 2006;163:1569–76.CrossRefGoogle Scholar
  23. 23.
    Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care. 2001;39:72–85.CrossRefGoogle Scholar
  24. 24.
    Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, Comes M, Colom F, Van Riel W, Ayuso-Mateos JL, Kapczinski F, Vieta E. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.CrossRefGoogle Scholar
  25. 25.
    Lam RW, Kennedy SH, Parikh SV, MacQueen GM, Milev RV, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatr. 2016;61:506–9.CrossRefGoogle Scholar
  26. 26.
    Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry Res. 2012;196:145–53.CrossRefGoogle Scholar
  27. 27.
    Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999;29:869–78.CrossRefGoogle Scholar
  28. 28.
    Godard J, Grondin S, Baruch P, Lafleur MF. Psychosocial and neurocognitive profiles in depressed patients with major depressive disorder and bipolar disorder. Psychiatry Res. 2011;190:244–52.CrossRefGoogle Scholar
  29. 29.
    Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, Velyvis V, Kennedy SH, Lam RW, MacQueen GM, Milev RV, Ravindran AV, Uher R. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 2. Psychological treatments. Can J Psychiatr. 2016;61:524–39.CrossRefGoogle Scholar
  30. 30.
    Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med. 2017;47:414–25.CrossRefGoogle Scholar
  31. 31.
    Joyce S, Modini M, Christensen H, Mykletun A, Bryant R, Mitchell PB, Harvey SB. Workplace interventions for common mental disorders: a systematic meta-review. Psychol Med. 2016;46:683–97.CrossRefGoogle Scholar
  32. 32.
    Porter RJ, Bourke C, Carter JD, Douglas KM, McIntosh VV, Jordan J, Joyce PR, Frampton CM. No change in neuropsychological dysfunction or emotional processing during treatment of major depression with cognitive-behaviour therapy or schema therapy. Psychol Med. 2016;46:393–404.CrossRefGoogle Scholar
  33. 33.
    Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013;18:139–49.CrossRefGoogle Scholar
  34. 34.
    Katsumi A, Hoshino H, Fujimoto S, Yabe H, Ikebuchi E, Nakagome K, Niwa SI. Effects of cognitive remediation on cognitive and social functions in individuals with schizophrenia. Neuropsychol Rehabil. 2017;1–13.Google Scholar
  35. 35.
    Ikebuchi E, Sato S, Yamaguchi S, Shimodaira M, Taneda A, Hatsuse N, Watanabe Y, Sakata M, Satake N, Nishio M, Ito JI. Does improvement of cognitive functioning by cognitive remediation therapy effect work outcomes in severe mental illness? A secondary analysis of a randomized controlled trial. Psychiatry Clin Neurosci. 2017;71:301–8.CrossRefGoogle Scholar
  36. 36.
    Hill NT, Mowszowski L, Naismith SL, Chadwick VL, Valenzuela M, Lampit A. Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis. Am J Psychiatry. 2017;174:329–40.CrossRefGoogle Scholar
  37. 37.
    Bowie CR, Gupta M, Holshausen K. Cognitive remediation therapy for mood disorders: rationale, early evidence, and future directions. Can J Psychiatr. 2013;58:319–25.CrossRefGoogle Scholar
  38. 38.
    Motter JN, Pimontel MA, Rindskopf D, Devanand DP, Doraiswamy PM, Sneed JR. Computerized cognitive training and functional recovery in major depressive disorder: a meta-analysis. J Affect Disord. 2016;189:184–91.CrossRefGoogle Scholar
  39. 39.
    Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatr. 2016;61:540–60.CrossRefGoogle Scholar
  40. 40.
    Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression--a systematic review. Psychiatry Res. 2014;219:25–50.CrossRefGoogle Scholar
  41. 41.
    Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28:32–72.CrossRefGoogle Scholar
  42. 42.
    Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the Digit Symbol Substitution Test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21:97–107.CrossRefGoogle Scholar
  43. 43.
    Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19, pii: pyv082.Google Scholar
  44. 44.
    Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40:2025–37.CrossRefGoogle Scholar
  45. 45.
    Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206–21.CrossRefGoogle Scholar
  46. 46.
    Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. The effects of newer antidepressants on occupational impairment in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30:405–17.CrossRefGoogle Scholar
  47. 47.
    Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93–105.CrossRefGoogle Scholar
  48. 48.
    Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31:569–76.CrossRefGoogle Scholar
  49. 49.
    Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–65.CrossRefGoogle Scholar
  50. 50.
    McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78:115–21.CrossRefGoogle Scholar
  51. 51.
    Bilsker D, Wiseman S, Gilbert M. Managing depression-related occupational disability: a pragmatic approach. Can J Psychiatr. 2006;51:76–83.CrossRefGoogle Scholar
  52. 52.
    Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2018;1–10.Google Scholar
  53. 53.
    Lam RW, Iverson GL, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. J Affect Disord. 2016;203:55–61.CrossRefGoogle Scholar
  54. 54.
    Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, Lam RW. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2017;32:343–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of British ColumbiaVancouverCanada
  2. 2.Djavad Mowafaghian Centre for Brain HealthVancouverCanada
  3. 3.Department of PsychiatryUniversity of MichiganAnn ArbourUSA

Personalised recommendations